Company intelligence
Novartis Belux
We reimagine medicine to improve and extend people’s lives in Belgium and Luxembourg.
About Novartis Belux
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. In Belgium, we are proud to be one of the leading life sciences companies with a legacy of more than a century. We focus on core therapeutic areas with high unmet patient needs: cardiovascular, renal and metabolic, oncology, immunology and neuroscience. Our people are our greatest strength: their diversity, energy and creativity are crucial to our success. They make our business by discovering, developing and facilitating access to our medicines. About 78,000 people of 140 nationalities work at Novartis around the world, with over 1,750 in Belgium in three locations including a production site in Puurs. Welcome to our BeLux page. Please take a look at our Community Guidelines: http://www.novartis.be/linkedin-community-guidelines for details about how to use and interact with our LinkedIn page.
Verified activity
Signals from Novartis Belux
6 published signals
People
Novartis Belux appointed GAFAR VICTOIR COULIDIATY as a clinical research medical advisor.
Reported by Novartis Belux
Research & Knowledge
Novartis Belux reports that over 75% of breast cancers in Belgium are detected at an early stage, offering patients a better prognosis.
Reported by Novartis Belux
Research & Knowledge
Novartis Belux notes that the risk of recurrence remains a reality in Belgium.
Reported by Novartis Belux
Research & Knowledge
Novartis Belux highlights collaborations and initiatives such as the #WanderBoobs activation campaign and the Samy book to support families.
Reported by Novartis Belux
People
Novartis Belux welcomed Sarah Bonhomme as Country President for Novartis in Belgium and Luxembourg starting from September 1, 2026.
Reported by Novartis Belux
People
Novartis Belux thanked Federico Mambretti for his leadership and dedication over the past five years.
Reported by Novartis Belux